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Abstract
Background: Little is known about family members’ interrelated decisions to seek genetic testing for
breast cancer susceptibility.
Methods: The speciﬁc aims of this cross-sectional, descriptive, cohort study were (i) to examine
whether individual and family characteristics have a direct effect on women’s decisions to use genetic
testing for hereditary susceptibility to breast cancer and (ii) to explore whether family characteristics
moderate the relationships between individual characteristics and the decision to use genetic testing.
Participants were women (>18 years old) who (i) received genetic testing for hereditary breast cancer
and who agreed to invite one of their female relatives into the study and (ii) female relatives who had
NOT obtained genetic testing and were identiﬁed by pedigree analysis as having >10% chances of
hereditary susceptibility to breast cancer.
Results: The ﬁnal sample consisted of 168 English-speaking, family dyads who completed self-
administered, mailed surveys with validated instruments. Multivariate conditional logistic regression
analyses showed that the proposedmodel explained 62%of the variance in genetic testing. The factorsmost
signiﬁcantly associated with genetic testing were having a personal history of cancer; perceiving genetic
testing to havemore beneﬁts than barriers; having greater family hardiness; and perceiving fewer negative
consequences associated with a breast cancer diagnosis. No signiﬁcant interaction effects were observed.
Conclusions: Findings suggest that both individual and family characteristics are associated with
the decision to obtain genetic testing for hereditary breast cancer; hence, there is a need for interven-
tions that foster a supportive family environment for patients and their high-risk relatives.
Copyright © 2012 John Wiley & Sons, Ltd.
Introduction
Approximately 10% of new breast cancer cases are caused
bymutations in highly penetrant genes that are passed down
in families; mutations in the Breast Cancer 1 and Breast
Cancer 2 (BRCA1/2) genes account for most of these
cases [1–5]. Women carrying a BRCA1/2 mutation have a
substantially elevated lifetime risk of developing breast
cancer (up to 85%) and/or ovarian cancer (40–60%) (OMIM
113705 and OMIM 600185) [6–8]. Women carrying a
BRCA1/2 mutation, who are already affected with breast
cancer, have a signiﬁcantly higher risk of developing a
second primary breast cancer or ovarian cancer [9,10].
Documenting hereditary susceptibility to breast cancer is a
critical step in the early detection, prevention, and clinical
management of the disease. Strategies, such as increased sur-
veillance, chemoprevention, and risk-reducing surgery, are
possible once mutation status is established [11–14]. Breast
cancer patients may beneﬁt from this information before
making surgical decisions, such as prophylactic mastectomy
and/or salpingo-oophorectomy. Because the age of onset for
hereditary tumors is substantially lower than for sporadic
breast cancers, cancer-free women with hereditary suscepti-
bility need access to surveillance at a younger age. These
women can also use information obtained from genetic test-
ing to make informed life decisions (e.g., reproduction) and
to take proactive steps and lower their cancer risk.
Despite these beneﬁts, use of genetic testing among
high-risk individuals has been lower than expected. Rates
of BRCA1/2 testing have been reported to be between 26%
and 80% [15,16]. Thus, the challenge is to identify factors
that are associated with this decision. Little is known
about family members’ interrelated decisions for BRCA1/2
testing. This study used a theoretically guided approach to
examine family characteristics that inﬂuence decisions for
genetic testing and interactions between individual and
family characteristics.
Theoretical framework and literature review
The investigation of how individual and family characteris-
tics inﬂuence decisions about genetic testing was guided by
the integration of three theories: stress and coping [17],
decision making [18], and family systems in genetic illness
[19] (Figure 1). According to the theory of stress and
coping, a woman’s initial response to learning about her
hereditary cancer risk would be to appraise the level
of threat associated with this information. This initial
appraisal is followed by secondary appraisals of the level
of psychological distress caused by this threat and the avail-
ability of coping resources. These secondary appraisals
most likely include an assessment of the beneﬁts and
barriers of genetic testing. In cases of hereditary breast
cancer, the decision to use genetic testing has implications
for the whole family. Multiple family members are likely
to be involved, directly or indirectly, in assessments of
beneﬁts and barriers of genetic testing. Thus, input guided
by family relationships and family communication
Copyright © 2012 John Wiley & Sons, Ltd.
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determines the overall attractiveness of genetic testing
and shapes this decision-making process.
There is empirical support for the strength of some of the
proposed relationships. High perceived risk of developing
cancer has been associated with greater frequency of genetic
testing [20,21]. Incomplete or inaccurate knowledge of
breast cancer genetics has been associated with low rates
of testing [22]. Although high psychological distress has
been associated with increased use of genetic testing [23],
it has also been linked to decreased ability to understand
genetic information and to make informed decisions
[21,24]. Genetic testing is less likely when perceived
barriers (e.g., lack of access to quality care or concern about
abuse of test results) outweigh perceived beneﬁts [25–27].
There is less evidence about the role that the family
environment plays in decisions about genetic testing. Most
studies examined the role of family environment in disclo-
sure of genetic test results. Family communication affects
what genetic information will be shared and with whom
[28]. Women are more likely to communicate genetic test
results with close relatives, such as their sisters, and with
younger family members [29–31]. Individuals without
identiﬁed mutations disclose genetic test results to fewer
relatives compared with mutation carriers [30–32]. Genetic
testing is more likely to be discussed among families with
higher cohesiveness and lower family conﬂict [33]. Family
members often disagree as to whether genetic testing is a
personal or a family decision, which may lead to conﬂict
about disclosure of test results [26,34,35]. However, to date
few studies have examined the relationship between family
characteristics and the actual decision to use genetic testing.
It has been suggested that an unsupportive family environ-
ment has been associated with low rates of testing
[36–40]. However, more information is necessary in order
to provide decision support to families who harbor cancer-
predisposing mutations.
The speciﬁc aims of the studywere (i) to examine whether
individual and family characteristics have a direct effect on
women’s decisions to use genetic testing for hereditary
breast cancer and (ii) to explore whether family characteris-
tics moderate the relationships between individual character-
istics and the decision to use genetic testing (Figure 1).
Methods
Design, setting, eligibility criteria, and recruitment
procedures
Participants for this cross-sectional, descriptive, cohort
study were obtained from two genetics clinics at a large
comprehensive cancer center. The two clinics provide risk
assessment, genetic counseling, and testing for mutations
associated with different hereditary cancers. Individuals
attending the clinics are either referred by a healthcare
provider or are self-referred. If the chance of carrying a
germline mutation is greater than 10%, genetic testing is
recommended; otherwise, it is discouraged but not denied.
The study recruited two cohorts: women who had
received genetic testing for BRCA1/2 mutations (probands)
and one of their female relatives who did NOT have genetic
testing. All participants were female, English-speaking, and
age 18 years or older. The study focused on women with
hereditary susceptibility to breast cancer because women
are more likely to communicate about breast cancer genetics
with other women in their family [29].
Probands were eligible to participate if their test result
was positive or indeterminate/uninformative for BRCA1/2
mutation, and if they agreed to invite one of their high-risk
Figure 1. Theoretical framework
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relatives into the study. Relatives were eligible if pedigree
analysis revealed that they had a >10% chance of heredi-
tary susceptibility to breast cancer, but they did NOT have
genetic testing. Pedigree analysis is based on the degree of
relatedness between the proband and her relatives and the
results of genetic testing. Because BRCA1/2 mutations
are inherited with an autosomal-dominant pattern, in cases
of an identiﬁed mutation ﬁrst-degree relatives have 50%
chance of carrying the same mutation, second-degree rela-
tives have 25% chance, and third-degree relatives have
12.5% chance. In cases of an indeterminate/uninformative
test result, pedigree analysis takes into consideration fam-
ily size and the family side hypothesized to harbor a delete-
rious mutation. An ‘indeterminate/uninformative’ test result
means (i) a person has a negative test result when family his-
tory is highly suggestive of hereditary breast/ovarian cancer
syndrome, or (ii) an unaffected individual has a negative test
result, and there is not an affected family member to test. In
such cases, it is recommended to test multiple family mem-
bers because the breast cancer seen in the family might be a
phenocopy (a change in phenotype arising from environ-
mental agent that mimics the effect of a mutation).
The study protocol was approved by the Institutional
Review Board. A genetic counselor reviewed the ﬁles of
women who had genetic testing for hereditary breast
cancer to identify eligible probands and potentially eligible
relatives. Probands who had at least one eligible relative
were sent an invitation letter and an informed consent
document. The invitation letter was tailored for each
proband and identiﬁed her potentially eligible female rela-
tives (e.g., sister, maternal/paternal aunt, niece, maternal/
paternal ﬁrst cousin). The letter explained that each proband
could invite the relative of her choice from those included
in the list but only if the relative had not been tested. The
invitation letter was followed by a phone call by the
genetic counselor to explain the study and to ascertain
the relatives’ eligibility. A self-administered survey was
mailed to probands agreeing to take part in the study,
along with an invitation letter, consent form, and a similar
self-administered survey for her relative. The relatives’
name and identifying information was not provided to
research staff until she consented to be in the study. Each
participant was compensated $20 for her time.
Instruments
Demographics, personal history of cancer, and surgical
history were based on self-report. Table 1 provides informa-
tion about the validity and reliability of the instruments used
to measure individual and family characteristics. Perceived
riskwas assessed by asking participants to rate their chances
of developing breast cancer compared with other women in
their family. This item was developed on the assumption
that family members are part of complex networks in which
risk appraisals are formulated and evaluated at a collective
familial level [41]. Perceived cause was assessed with
two scales that evaluate knowledge of genetic inheritance
and knowledge of breast cancer risk factors [42,43];
Table 1. Characteristics of instruments
Construct Concept Instrument
Cronbach’s
alpha
Test–
retest
reliability
Individual
characteristics
Perceived risk
breast cancer
‘Rate your chances of developing breast cancer
compared with other women in your family.’
— —
Likert type; range 1 ‘a lot lower’ to 7 ‘a lot higher’
Developed for the study
Perceived cause Knowledge of modes of gene inheritance:
15 multiple choice items about breast cancer genetics.
0.82 —
Previously tested with high-risk women [43]
Knowledge of HBOC risk factors: 19 items; answers
‘yes’ ‘no’ ‘do not know’. Earlier version used with
a sample including 15% of high-risk women [42]
0.89 —
Perceived severity Subscale of IPQ-R; Likert type; range 1 ‘strongly
disagree’ to 7 ‘strongly agree’. Used with
breast cancer patients and healthy controls [53]
0.78 0.48–0.88
Perceived controllability Subscale of IPQ-R; Likert type; range 1 ‘strongly
disagree’ to 7 ‘strongly agree’. Used with
breast cancer patients and healthy controls [53]
0.79 0.48–0.88
Psychological
distress
Psychological
distress breast
and ovarian cancer
‘How often you were worried’ and ‘How emotionally
upset or distressed you had been’ about the possibility
of developing breast cancer ; range from 1 ‘never/not
at all’ to 10 ‘all the time/a great deal’. Used with a
sample containing 15% of high-risk women [45]
0.90 —
Perceived utility
of genetic testing
Perceived beneﬁts–
perceived barriers
Perceived beneﬁts; 8 Likert-type items; range 1 ‘strongly
disagree’ to 7 ‘strongly agree’. Perceived barriers;
7 Likert-type items; range 1 ‘strongly disagree’ to 7 ‘strongly
agree’. Used with women undergoing genetic testing [25]
0.80 and 0.71 —
Family characteristics Family relationships Family Relationships Inventory; 27 Likert-type items; range 1
‘never’ to 7 ‘always’. Used with high-risk families [46]
0.79 0.75
Family communication Family Problem Solving and Communication Index;
10 Likert-type items; range 1 ‘never’ to 7 ‘always’ [47]
0.89 0.86
Family hardiness Family Hardiness Scale; 20 Likert-type items; range 1 ‘never’
to 7 ‘always’[48]
0.92 0.78–0.86
HBOC, hereditary breast and ovarian cancer; IPQ-R, Revised-Illness Perceptions Questionnaire.
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higher scores indicated greater knowledge (scores were
summed). Perceived severity (i.e., negative consequences
of breast cancer) and perceived controllability were
measured with subscales of the Revised-Illness Perceptions
Questionnaire [44]. Psychological distress was measured
with previously validated items [45]. A composite score
from two subscales assessing perceived beneﬁts and barriers
of genetic testing measured perceived utility of genetic
testing [25]. Family relationship was assessed with the
Family Relationships Inventory [46] that evaluates family
cohesion, expressiveness in communication, and conﬂict
resolution. The Family ProblemSolving and Communication
Index [47], used to assess family communication, measures
incendiary and afﬁrming family communication, and how
families manage tension and acquire functioning, adjust-
ment, and adaptation. Family hardiness measures cohesion
and ability to cope with adverse events [48].
Data analyses
Missing data were assessed with Proc MI in SAS version 9
(SAS Institute Inc. NC, USA) and missing values for
psychosocial instruments were imputed [49] (SAS MI pro-
cedure). Descriptive statistics were used to describe demo-
graphic characteristics and survey responses. Conditional
logistic regression analysis, which accounted for the
matched observations (proband-relative dyads) and for the
dichotomous primary outcome (genetic testing: yes/no)
were conducted in SAS version 9. Relationships between
predictive variables and the outcome were tested in a
three-step process: (i) variables were initially tested in uni-
variate conditional logistic regressions; (ii) those that were
signiﬁcantly associated with genetic testing were tested to-
gether in a multivariate model; and (iii) moderation analyses
examined if family characteristics (i.e., relationships, com-
munication, and hardiness) moderated the effect of individ-
ual characteristics on the decision to have genetic testing.
Power analysis indicated that with alpha of 0.05, a sample
of 147 matched proband-relative dyads (pairs) would
provide 80% power to detect moderate correlations among
the predictive variables and the outcome (R2 = 0.13).
Results
The project recruited an overall sample of N=372 partici-
pants including 200 probands and 172 of their female
relatives. Thirty-two probands withdrew from the study
because all high-risk relatives have been tested (n=6);
eligible relatives did not agree to participate (n=12); they
did not have enough time (n=3); they were too upset,
distressed, worried (n=7); or for no reason (n=4). The ﬁnal
sample in this analysis includes 168 matched proband-
relative dyads (N=336 participants), where both the
proband and the relative completed and returned their survey.
Demographics of the sample included the following:
Caucasian (95%), married or had a life partner (73%),
employed full-time or part-time (66%), had health insurance
(96%), and income ≥$61,000 (61%). Probands were on
average 30 months post-genetic testing (range 2–58).
Table 2 presents additional demographic and health infor-
mation for probands and relatives. Probands were older
and more educated than relatives, but these differences were
not signiﬁcant. Most probands (86%) had a personal history
of cancer compared with 21% of relatives (p< 0.05).
Among the 168 matched dyads, n=23 probands (14%)
tested positive for a BRCA1/2 mutation (true positives).
The remaining n=145 probands who received a negative
test result were classiﬁed as ‘indeterminate/uninformative’.
The 168 high-risk relatives did not have genetic testing
and were of unknown mutation status. Almost half of the
relatives that participated in the study (52%) were ﬁrst-
degree relatives (n=45 sisters, n=31 daughters, n=11
mothers). Approximately 18%were second-degree relatives
(n=14 aunts, n=16 nieces) and approximately 11% were
third-degree relatives (n=18 ﬁrst cousins). For 33 dyads
in the study (20%), the degree of relatedness could not be
determined from the data provided.
Table 2. Characteristics of the two cohorts
Probands (N=168) Relatives (N=168)
51 (SD=11) range: 22–83 48 (SD=16) range: 18–81
N % N %
Age (years)
<25 — — 14 8
25–39 24 14 39 23
40–64 114 68 90 54
>65 17 10 22 13
Missing 13 8 3 2
Education
< Bachelor’s degree 55 32 77 46
≥ Bachelor’s degree 113 68 91 54
Personal history of cancer
Breast (invasive, DCIS) 129 77 24 14
Ovarian 5 3 3 2
Other cancer 11 6 7 5
Surgery
Breast (lumpectomy, mastectomy) 129 77 24 14
Oophorectomy 48 29 28 17
Mutation status
Positive BRCA1 or BRCA2 mutation 29 17 — —
DCIS, ductal cell carcinoma in situ; BRCA1 and BRCA2, Breast Cancer 1 and Breast Cancer 2.
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Univariate analyses
Variables that were positively associated with genetic
testing in the univariate conditional regression analyses
were education (OR=1.23, p=0.01); personal history of
cancer (OR=5.12, p< 0.0001); perceived risk (OR=1.45,
p< 0.0001); perceived cause (OR=1.65, p< 0.0001);
psychological distress (OR=1.12, p=0.03); perceived
utility of genetic testing (OR=2.30, p< 0.0001); and family
hardiness (OR=1.36, p=0.02). Perceived severity (OR=
0.49, p< 0.0001) and perceived controllability (OR=0.72,
p=0.04) were negatively associated with genetic testing
(Table 3).
Multivariate analysis
Variables associated with genetic testing in the univariate
analyses were tested with a multivariate logistic regression
model (Table 4). The model explained 62% of the variance
in genetic testing (max-rescaled R-square = 0.62). Having a
personal history of cancer was the most signiﬁcant variable
associated with genetic testing (OR=4.76, p=0.009); after
holding other variables ﬁxed, there was a 376% increase in
the odds of genetic testing after having a cancer diagnosis.
Perceived utility of genetic testing was the second most
signiﬁcant variable associated with genetic testing
(OR = 1.97, p = 0.009); after holding other variables
ﬁxed, there was a 97% increase in the odds of genetic
testing for one-unit increase in perceived utility. Family
hardiness was the third most signiﬁcant variable associ-
ated with genetic testing (OR= 1.29, p = 0.04); after
holding other variables ﬁxed, there was a 29% increase
in the odds of genetic testing for one-unit increase in the
family hardiness index. Finally, perceived severity was the
fourth variable signiﬁcantly associated with genetic testing
(OR=0.52, p=0.02); after holding other variables ﬁxed,
there was a 52% decrease in the odds of genetic testing for
one-unit increase in perceived severity of breast cancer.
Interactions between individual and
family characteristics
Data were analyzed for possible interactions between indi-
vidual and family characteristics (Figure 1, Aim 2). There
were no signiﬁcant interactions. Only the term ‘family
communication * perceived cause’ approached statistical
signiﬁcance (OR= 1.22, p= 0.055).
Discussion
This study examined individual and familial characteristics
associated with genetic testing for hereditary susceptibility
to breast cancer in two related cohorts of women: probands
who had genetic testing and one of their high-risk female
relatives who had not been tested. Probands had received
genetic counseling and most had a personal cancer diag-
nosis. In contrast, their relatives did not have genetic
testing and fewer had a personal cancer history. These
differences between the two cohorts are taken into
account when interpreting study ﬁndings.
Consistent with other studies [29–31], probands were
more likely to select their ﬁrst-degree relatives and mostly
their sisters to invite in the study. Relatives were on
Table 3. Univariate conditional logistic regression analyses
Predictor Odds ratio Estimate Wald chi-square p-value
Age 0.93 0.07 0.09 0.77
Income 1.35 0.30 1.61 0.21
Education 1.23 0.20 6.04 0.01
Personal history of cancer 5.12 1.63 42.82 <0.001
Personal history of surgery 1.44 0.37 1.94 0.16
Perceived risk HBOC 1.45 0.37 15.91 <0.001
Perceived cause HBOC 1.65 0.53 29.63 <0.001
Perceived severity HBOC 0.49 1.02 21.39 <0.001
Perceived controllability 0.72 0.33 3.74 0.05
Psychological distress HBOC 1.12 0.06 2.76 0.03
Perceived utility of genetic testing 2.30 1.39 31.05 <0.001
Family relationships 1.52 0.42 1.02 0.31
Family problem solving communication 1.15 1.14 0.44 0.51
Family Hardiness Index 1.36 1.03 5.61 0.02
Bold emphasis is used to identify statistically signiﬁcant relationships.
HBOC, hereditary breast and ovarian cancer.
Table 4. Multivariate conditional logistic regression analysis
Predictor Odds ratio Estimate Wald chi-square p-value
Education 1.38 0.32 0.44 0.51
Personal history of cancer 4.76 3.74 6.90 0.01
Perceived risk HBOC 1.29 0.25 0.47 0.49
Perceived cause HBOC 2.13 0.75 2.76 0.10
Perceived severity HBOC 0.52 1.68 4.05 0.02
Perceived controllability 0.74 0.30 0.15 0.70
Psychological distress HBOC 1.14 0.42 1.02 0.15
Perceived utility of genetic testing 1.97 3.32 6.83 0.01
Family Hardiness Index 1.29 3.22 3.60 0.04
HBOC, hereditary breast and ovarian cancer.
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average younger than probands, which is consistent with
previous reports that younger age of the relative is a
predictor of communication of genetic information [29].
Communication of test results occurs primarily among
nuclear families and ﬁrst-degree relatives [22,28,37]. This
means that more distant family members, such as second-
degree and third-degree relatives, who may also beneﬁt
from the genetic information, are often left out of this com-
munication process. This has signiﬁcant clinical and ethical
implications and points to an area for further intervention.
The present study focused on examining individual and
family predictors of BRCA1/2 testing. Variables most
signiﬁcantly associated with genetic testing were having
a personal cancer diagnosis and perceiving genetic testing
to have more beneﬁts than barriers. These ﬁndings are
consistent with other studies reporting that most women
who present for genetic testing already have a personal
cancer diagnosis [21,50] and believe that genetic testing
has more beneﬁts than barriers [25]. Women already
affected by breast cancer are the best candidates for
genetic testing compared with other family members.
Thus, it is not surprising that most probands in the study
had a personal cancer diagnosis. However, this ﬁnding
can also be partially interpreted as a failure of the health-
care system to screen and identify high-risk individuals
when they are still unaffected by cancer. This could signif-
icantly reduce morbidity from hereditary breast cancer
and associated healthcare costs. Findings highlight the need
for new strategies that increase early identiﬁcation of high-
risk women and appropriate referrals to genetic counseling.
Genetic testing was positively associated with higher
family hardiness, which is a new ﬁnding. Family hardiness
is a measure of family resiliency which can be deﬁned as
the family’s cohesion and ability to overcome adverse
events. We examined whether probands reported higher
family hardiness compared with relatives, but the difference
was not statistically signiﬁcant (data not shown). It is possi-
ble that probands, who reported greater family hardiness,
had also developed stronger family networks that increased
their coping resources for dealing with cancer diagnosis and
the stress associated with genetic testing. The retrospective
and cross-sectional design of this study does not allow
causal inferences between family hardiness and genetic
testing. A prospective cohort study is more appropriate to
further examine this association.
There was a negative association between genetic testing
and perceiving more negative consequences of breast
cancer. It is not uncommon for cancer-free women, like
most of the relatives in this study, to overestimate the nega-
tive consequences of breast cancer [51]. Genetic counseling
offered probands accurate information about their cancer
risk, the genetics of cancer, and options for risk manage-
ment. In contrast, relatives most likely did not have genetic
counseling and were informed about their potential suscep-
tibility to the disease by probands. This assumption is based
on a study by Lerman et al. [52], which reported that women
often commit to a decision about genetic testing before
they participate in counseling. The majority of women
who participate in counseling opt to be tested, whereas those
who decide not to be tested do not avail themselves of
genetic counseling [52]. Among relatives, the lack of
knowledge regarding cancer genetics and risk management
options may have contributed toward overestimation of the
negative consequences of the disease. This may lead to more
avoidant coping and less interest in obtaining genetic testing.
One signiﬁcant contribution of the study is the integra-
tion of stress and coping theory with decision-making
theory and the family systems in genetic illness theory.
Stress and coping theory has been adopted extensively in
the area of psychosocial research. A meta-analysis of 45
studies reported that many of the theory constructs have
been supported across different illnesses [53]. However,
stress and coping theory does not include family charac-
teristics and cannot fully explain the interrelated decisions
of high-risk family members about use of genetic testing.
The theoretical integration that guided this study provides
a comprehensive way of examining the individual and
familial context of genetic testing for hereditary suscepti-
bility to breast cancer.
Family communication may have a wide range of inﬂu-
ences on interrelated decisions for genetic testing. Empir-
ical evidence suggests that family cohesion and openness
may facilitate communication of genetic test results
[29,50]. It makes intuitive sense that members of families
with open communication would be more informed about
the genetics of breast cancer, whereas members of families
with less open communication will have inadequate and
inaccurate information and would be less likely to
have genetic testing. In this study, the moderation effect
between family communication and perceived cause
approached statistical signiﬁcance. Although power calcu-
lations indicated that the sample was adequate to answer
the primary aim, it is possible that the study was under-
powered to detect a moderation effect. Often moderation
effects are much smaller than the main effect, so a much
larger sample may be needed. Future studies should
further investigate this topic.
Limitations
First, personal history of cancer, surgical history, and lack of
genetic testing in relatives were based on self-reports and
may not be accurate. Limited participation of non-Caucasian
women and women diagnosed with ovarian cancer
decreases generalizability of ﬁndings. The decision-making
process about genetic testing is a dynamic phenomenon,
evolving over time, with input from medical diagnoses,
genetic information, and the family environment. The
cross-sectional and retrospective design of this study limits
our understanding of the effects of individual and family
characteristics when the actual decision about genetic
testing was made. Additional information, including
whether probands communicated test results to relatives,
how long after genetic testing, and whether there was ongo-
ing discussion about the relative being tested was not avail-
able. This information would have helped us better
understand the intra-familial decision-making process.
Finally, because of federal regulations regarding protection
of identiﬁable health information, the research team could
not recruit eligible relatives directly. Rather, probands
recruited relatives in the study. On one hand, this affected
variance in family relationships and family communication
because probands likely chose to recruit the relative they
feel close to or have higher stakes in her testing. On the other
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hand, this recruitment method targets women who have
higher-than-average breast cancer risk because of their
strong family history. Despite its limitations, this recruit-
ment method provides access to a community-dwelling
sample of women who could beneﬁt from an early detection
intervention. The large sample of the two related cohorts of
women and the comprehensive examination of individual
and family characteristics are also signiﬁcant contributions
of the study.
Clinical implications
This study provides evidence for the individual and family
characteristics that inﬂuence the decision to use genetic
testing for hereditary breast cancer. Given the rapid discov-
ery of cancer susceptibility genes, there is an increased need
for empirically validated methods that facilitate family care
for families with hereditary cancer syndromes. Genetic
information is unique, because it is both private to the indi-
vidual and also needs to be shared with family members.
Given the ramiﬁcations of genetic information for family
members, a shift in healthcare toward a family-based model
is imperative.
The need to include family members in the decision-
making process about genetic testing has been recognized
[54]. Decisional aids and educational tools about hereditary
cancer and genetic testing should address the needs of both
the proband and the family members involved in this
process. Although interventions to increase family partici-
pation during genetic counseling exist [57,58], there is great
variability in family involvement during this process and
potentially great variability in family care among different
clinical settings. Thus, identifying and intervening with
patients and families at greatest need for psychosocial care
when deciding about BRCA1/2 testing will enhance stan-
dards of care. Findings from this study point to the family
environment as an important new area for clinical interven-
tion during decision making about genetic testing. Family
relations are pre-existing structures that may function as
means of social support and enhance quality decision
making about genetic testing. Systematic assessment of
the family network and the coping resources at the familial
level is the ﬁrst step forward. Family-based interventions
that provide comprehensive communication, coping, and
decisional support about genetic testing are needed.
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